Thus, our study positions PRAJA1, along with its downstream targets like p-eEF2, spinophilin, and L-VGCCs, as a compelling therapeutic target for cognitive enhancement in AD and potentially other neurological disorders [40]. This evidence concerns the gene PJA1 and nervous system disorder.